Article
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
PLoS medicine - 1 Nov 2005
Greulich Heidi, Chen Tzu-Hsiu, Feng Whei, Jänne Pasi A, Alvarez James V, Zappaterra Mauro, Bulmer Sara E, Frank David A, Hahn William C, Sellers William R, Meyerson Matthew
Abstract excerpt
BACKGROUND: Somatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine kinase gene EGFR are common in lung adenocarcinoma. The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of spe...
Topics
- Adaptor Proteins, Signal Transducing
- Animals
- Antineoplastic Agents
- Cell Transformation, Neoplastic
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Exons
- Gefitinib
- Genetic Therapy
- Humans
- Mice
- Mice, Nude
- Mutation